<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36713460</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Research progress on circular RNA vaccines.</ArticleTitle><Pagination><StartPage>1091797</StartPage><MedlinePgn>1091797</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1091797</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1091797</ELocationID><Abstract><AbstractText>Owing to the success of linear mRNA coronavirus disease 2019 (COVID-19) vaccines, biopharmaceutical companies and research teams worldwide have attempted to develop more stable circular RNA (circRNA) vaccines and have achieved some preliminary results. This review aims to summarize key findings and important progress made in circRNA research, the <i>in vivo</i> metabolism and biological functions of circRNAs, and research progress and production process of circRNA vaccines. Further, considerations regarding the quality control of circRNA vaccines are highlighted herein, and the main challenges and problem-solving strategies in circRNA vaccine development and quality control are outlined to provide a reference for circRNA vaccine-related research.</AbstractText><CopyrightInformation>Copyright © 2023 Bai, Liu, He, Liu, Mao and Liang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079962">RNA, Circular</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079962" MajorTopicYN="N">RNA, Circular</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="Y">Biological Products</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">circular RNA vaccines</Keyword><Keyword MajorTopicYN="N">outlook</Keyword><Keyword MajorTopicYN="N">production process</Keyword><Keyword MajorTopicYN="N">quality control</Keyword><Keyword MajorTopicYN="N">research progress</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>30</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36713460</ArticleId><ArticleId IdType="pmc">PMC9878156</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1091797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>He Q, Mao Q, Zhang J, Bian L, Gao F, Wang J, et al. . COVID-19 vaccines: Current understanding on immunogenicity, safety, and further considerations. Front Immunol (2021) 12:669339. doi: 10.3389/fimmu.2021.669339</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.669339</ArticleId><ArticleId IdType="pmc">PMC8071852</ArticleId><ArticleId IdType="pubmed">33912196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Xu M, He Q, Li C, Meng S, Wang Y, et al. . COVID-19 vaccines: progress and understanding on quality control and evaluation. Signal Transduct Target Ther (2021) 6(1):199. doi: 10.1038/s41392-021-00621-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00621-4</ArticleId><ArticleId IdType="pmc">PMC8129697</ArticleId><ArticleId IdType="pubmed">34006829</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Mao Q, Wu X, He Q, Bian L, Bai Y, et al. . Considerations for the feasibility of neutralizing antibodies as a surrogate endpoint for COVID-19 vaccines. Front Immunol (2022) 13:814365. doi: 10.3389/fimmu.2022.814365</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.814365</ArticleId><ArticleId IdType="pmc">PMC9092276</ArticleId><ArticleId IdType="pubmed">35572565</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Song Z, Yang J, He Q, Mao Q, Bai Y, et al. . Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV. Emerg Microbes Infect (2022) 11(1):1145–53. doi: 10.1080/22221751.2022.2059404</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2059404</ArticleId><ArticleId IdType="pmc">PMC9037177</ArticleId><ArticleId IdType="pubmed">35343384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb YN. BNT162b2 mRNA COVID-19 vaccine: First approval. Drugs (2021) 81(4):495–501. doi: 10.1007/s40265-021-01480-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01480-7</ArticleId><ArticleId IdType="pmc">PMC7938284</ArticleId><ArticleId IdType="pubmed">33683637</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. Jama (2021) 325(13):1318–20. doi: 10.1001/jama.2021.3199</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3199</ArticleId><ArticleId IdType="pubmed">33635317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. . Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther (2022) 7(1):94. doi: 10.1038/s41392-022-00950-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00950-y</ArticleId><ArticleId IdType="pmc">PMC8940982</ArticleId><ArticleId IdType="pubmed">35322018</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, et al. . mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther (2022) 7(1):166. doi: 10.1038/s41392-022-01007-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01007-w</ArticleId><ArticleId IdType="pmc">PMC9123296</ArticleId><ArticleId IdType="pubmed">35597779</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO coronavirus (COVID-19) dashboard. Available at: https://www.who.int/redirect-pages/page/novel-coronavirus-(covid-19)-situation-dashboard.</Citation></Reference><Reference><Citation>Lozano-Ojalvo D, Camara C, Lopez-Granados E, Nozal P, Del Pino-Molina L, Bravo-Gallego LY, et al. . Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep (2021) 36(8):109570. doi: 10.1016/j.celrep.2021.109570</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109570</ArticleId><ArticleId IdType="pmc">PMC8332924</ArticleId><ArticleId IdType="pubmed">34390647</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. . Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med (2021) 27(11):1990–2001. doi: 10.1038/s41591-021-01507-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01507-2</ArticleId><ArticleId IdType="pmc">PMC8604727</ArticleId><ArticleId IdType="pubmed">34522051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. . COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature (2020) 586(7830):594–9. doi: 10.1038/s41586-020-2814-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, et al. . mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest (2020) 130(11):5976–88. doi: 10.1172/jci134915</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci134915</ArticleId><ArticleId IdType="pmc">PMC7598064</ArticleId><ArticleId IdType="pubmed">33016924</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitley J, Zwolinski C, Denis C, Maughan M, Hayles L, Clarke D, et al. . Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Transl Res (2022) 242:38–55. doi: 10.1016/j.trsl.2021.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8641981</ArticleId><ArticleId IdType="pubmed">34871810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer (2021) 20(1):33. doi: 10.1186/s12943-021-01311-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-021-01311-z</ArticleId><ArticleId IdType="pmc">PMC7884263</ArticleId><ArticleId IdType="pubmed">33593376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobiyama K, Ishii KJ. Making innate sense of mRNA vaccine adjuvanticity. Nat Immunol (2022) 23(4):474–6. doi: 10.1038/s41590-022-01168-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01168-4</ArticleId><ArticleId IdType="pubmed">35354958</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. The tangled history of mRNA vaccines. Nature (2021) 597(7876):318–24. doi: 10.1038/d41586-021-02483-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-02483-w</ArticleId><ArticleId IdType="pubmed">34522017</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt EA, Gerhardt A, Hanson D, Jennewein MF, Battisti P, Reed S, et al. . A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. NPJ Vaccines (2022) 7(1):136. doi: 10.1038/s41541-022-00549-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00549-y</ArticleId><ArticleId IdType="pmc">PMC9628444</ArticleId><ArticleId IdType="pubmed">36323666</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. . Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett (2017) 17(3):1326–35. doi: 10.1021/acs.nanolett.6b03329</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.6b03329</ArticleId><ArticleId IdType="pmc">PMC5523404</ArticleId><ArticleId IdType="pubmed">28273716</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell (2022) 185:2016–34. doi: 10.1016/j.cell.2022.04.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.04.021</ArticleId><ArticleId IdType="pubmed">35584701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ, Xu RH, et al. . Metabolism, functions and interactions with proteins. Mol Cancer (2020) 19(1):172. doi: 10.1186/s12943-020-01286-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-020-01286-3</ArticleId><ArticleId IdType="pmc">PMC7734744</ArticleId><ArticleId IdType="pubmed">33317550</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, et al. . Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell (2022) 185(10):1728–1744 e16. doi: 10.1016/j.cell.2022.03.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.044</ArticleId><ArticleId IdType="pmc">PMC8971115</ArticleId><ArticleId IdType="pubmed">35460644</ArticleId></ArticleIdList></Reference><Reference><Citation>Seephetdee C, Bhukhai K, Buasri N, Leelukkanaveera P, Lerdwattanasombat P, Manopwisedjaroen S, et al. . A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antiviral Res (2022) 204:105370. doi: 10.1016/j.antiviral.2022.105370</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105370</ArticleId><ArticleId IdType="pmc">PMC9235288</ArticleId><ArticleId IdType="pubmed">35772601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wei H, Zhang K, Li Z, Wei T, Tang C, et al. . A flexible, efficient, and scalable platform to produce circular RNAs as new therapeutics. bioRxiv preprint server Biol (2022). doi: 10.1101/2022.05.31.494115</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.31.494115</ArticleId></ArticleIdList></Reference><Reference><Citation>Patop IL, Wust S, Kadener S. Past, present, and future of circRNAs. EMBO J (2019) 38(16):e100836. doi: 10.15252/embj.2018100836</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018100836</ArticleId><ArticleId IdType="pmc">PMC6694216</ArticleId><ArticleId IdType="pubmed">31343080</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, Han W, Chen D, Zhao J, Bai L, Huang F, et al. . Engineering circular RNA regulators to specifically promote circular RNA production. Theranostics (2021) 11(15):7322–36. doi: 10.7150/thno.56990</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.56990</ArticleId><ArticleId IdType="pmc">PMC8210604</ArticleId><ArticleId IdType="pubmed">34158853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Lian P, Li J, Zhang Z, Qiao J. The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice. Microb Pathog (2021) 150:104645. doi: 10.1016/j.micpath.2020.104645</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104645</ArticleId><ArticleId IdType="pubmed">33285220</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Bai Yu, Yang J, Lu S, Mao Q, Gao F, et al. . B.1.351 SARS-CoV-2 variant exhibits higher virulence but LessViral shedding than that of the ancestral strain in YoungNonhuman primates. Microbiol Spectr (2022) 10(5):e0226322. doi: 10.1128/spectrum.02263-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02263-22</ArticleId><ArticleId IdType="pmc">PMC9603226</ArticleId><ArticleId IdType="pubmed">36069561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, Bai Yu, Gao F, Liu M, He Q, Wu X, et al. . Effective protection of ZF2001 against the SARS-CoV-2 delta variant in lethal K18-hACE2 mice. Virol J (2022) 19(1):86. doi: 10.1186/s12985-022-01818-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01818-x</ArticleId><ArticleId IdType="pmc">PMC9122244</ArticleId><ArticleId IdType="pubmed">35596222</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsagris EM, Martinez de Alba AE, Gozmanova M, Kalantidis K. Viroids. Cell Microbiol (2008) 10(11):2168–79. doi: 10.1111/j.1462-5822.2008.01231.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2008.01231.x</ArticleId><ArticleId IdType="pubmed">18764915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanger GKHL, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-pairedrod-like structures. Proc NatI. Acad Sci (1976) 73(11):3852–6. doi: 10.1073/pnas.73.11.3852</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.73.11.3852</ArticleId><ArticleId IdType="pmc">PMC431239</ArticleId><ArticleId IdType="pubmed">1069269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature (1979) 280(5720):339–40. doi: 10.1038/280339a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/280339a0</ArticleId><ArticleId IdType="pubmed">460409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge LQ, Huang B, Jiang YP, Gu HT, Xia T, Yang GQ, et al. . Carboxylesterase precursor (EST-1) mediated the fungicide jinggangmycin-suppressed reproduction of sogatella furcifera (Hemiptera: Delphacidae). J economic entomology (2017) 110(5):2199–206. doi: 10.1093/jee/tox201</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jee/tox201</ArticleId><ArticleId IdType="pubmed">28981692</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocquerelle C, Mascrez B, Hetuin D, Bailleul B. Mis-splicing yields circular RNA molecules. FASEB J (1993) 7(1):155–60. doi: 10.1096/fasebj.7.1.7678559</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.7.1.7678559</ArticleId><ArticleId IdType="pubmed">7678559</ArticleId></ArticleIdList></Reference><Reference><Citation>Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, et al. . Circular transcripts of the testis-determining gene sry in adult mouse testis. Cell (1993) 73(5):1019–30. doi: 10.1016/0092-8674(93)90279-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90279-y</ArticleId><ArticleId IdType="pubmed">7684656</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocquerelle C, Daubersies P, Majerus MA, Kerckaert JP, Bailleul B. Splicing with inverted order of exons occurs proximal to large introns. EMBO J (1992) 11(3):1095–8. doi: 10.1002/j.1460-2075.1992.tb05148.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1992.tb05148.x</ArticleId><ArticleId IdType="pmc">PMC556550</ArticleId><ArticleId IdType="pubmed">1339341</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubin RA, Kazmi MA, Ostrer H. Inverted repeats are necessary for circularization of the mouse testis sry transcript. Gene (1995) 167(1-2):245–8. doi: 10.1016/0378-1119(95)00639-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1119(95)00639-7</ArticleId><ArticleId IdType="pubmed">8566785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaphiropoulos PG. Exon skipping and circular RNA formation in transcripts of the human cytochrome p-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol Cell Biol (1997) 17(6):2985–93. doi: 10.1128/mcb.17.6.2985</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.17.6.2985</ArticleId><ArticleId IdType="pmc">PMC232150</ArticleId><ArticleId IdType="pubmed">9154796</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasman Z, Been MD, Garcia-Blanco MA. Exon circularization in mammalian nuclear extracts. RNA (1996) 2(6):603–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369399</ArticleId><ArticleId IdType="pubmed">8718689</ArticleId></ArticleIdList></Reference><Reference><Citation>Houseley JM, Garcia-Casado Z, Pascual M, Paricio N, O'Dell KM, Monckton DG, et al. . Noncanonical RNAs from transcripts of the drosophila muscleblind gene. J Hered (2006) 97(3):253–60. doi: 10.1093/jhered/esj037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jhered/esj037</ArticleId><ArticleId IdType="pubmed">16714427</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Yang L, Chen LL. Characterization of circular RNAs. Methods Mol Biol (2021) 2372:179–92. doi: 10.1007/978-1-0716-1697-0_16</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1697-0_16</ArticleId><ArticleId IdType="pubmed">34417752</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PloS One (2012) 7(2):e30733. doi: 10.1371/journal.pone.0030733</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030733</ArticleId><ArticleId IdType="pmc">PMC3270023</ArticleId><ArticleId IdType="pubmed">22319583</ArticleId></ArticleIdList></Reference><Reference><Citation>Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. . Circular RNAs are a large class of animal RNAs with regulatory potency. Nature (2013) 495(7441):333–8. doi: 10.1038/nature11928</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11928</ArticleId><ArticleId IdType="pubmed">23446348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, et al. . Circular intronic long noncoding RNAs. Mol Cell (2013) 51(6):792–806. doi: 10.1016/j.molcel.2013.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2013.08.017</ArticleId><ArticleId IdType="pubmed">24035497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol (2014) 32(5):453–61. doi: 10.1038/nbt.2890</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2890</ArticleId><ArticleId IdType="pmc">PMC4121655</ArticleId><ArticleId IdType="pubmed">24811520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XO, Wang HB, Zhang Y, Lu X, Chen LL, Yang L. Complementary sequence-mediated exon circularization. Cell (2014) 159(1):134–47. doi: 10.1016/j.cell.2014.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.09.001</ArticleId><ArticleId IdType="pubmed">25242744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagawa T, Kopardé VN, Ziegelbauer JM. Identifying and characterizing virus-encoded circular RNAs. Methods (2021) 196:129–37. doi: 10.1016/j.ymeth.2021.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2021.03.004</ArticleId><ArticleId IdType="pmc">PMC8445388</ArticleId><ArticleId IdType="pubmed">33713796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzoni I. Widespread occurrence of circular RNA in eukaryotes. Nat Rev Genet (2021) 22(9):550–1. doi: 10.1038/s41576-021-00375-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-021-00375-3</ArticleId><ArticleId IdType="pubmed">34017103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper S, Wadsworth ES, Ochsenreiter T, Ivens A, Savill NJ, Schnaufer A. Assembly and annotation of the mitochondrial minicircle genome of a differentiation-competent strain of trypanosoma brucei. Nucleic Acids Res (2019) 47(21):11304–25. doi: 10.1093/nar/gkz928</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz928</ArticleId><ArticleId IdType="pmc">PMC6868439</ArticleId><ArticleId IdType="pubmed">31665448</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo L, Zhang P, Li C, Rahim K, Hao X, Xiang B, et al. . Genome-wide identification of circRNAs in pathogenic basidiomycetous yeast cryptococcus neoformans suggests conserved circRNA host genes over kingdoms. Genes (2018) 9(3):118. doi: 10.3390/genes9030118</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes9030118</ArticleId><ArticleId IdType="pmc">PMC5867839</ArticleId><ArticleId IdType="pubmed">29495353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Z. Efficient backsplicing produces translatable circular mRNAs. RNA (2015) 21(2):172–9. doi: 10.1261/rna.048272.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.048272.114</ArticleId><ArticleId IdType="pmc">PMC4338345</ArticleId><ArticleId IdType="pubmed">25449546</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YG, Kim MV, Chen X, Batista PJ, Aoyama S, Wilusz JE, et al. . Sensing self and foreign circular RNAs by intron identity. Mol Cell (2017) 67(2):228–238.e5. doi: 10.1016/j.molcel.2017.05.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.05.022</ArticleId><ArticleId IdType="pmc">PMC5610545</ArticleId><ArticleId IdType="pubmed">28625551</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobi T, Dieterich C. Computational approaches for circular RNA analysis. Wiley Interdiscip Rev RNA (2019) 10(3):e1528. doi: 10.1002/wrna.1528</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.1528</ArticleId><ArticleId IdType="pubmed">30788906</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey PR, Munk R, Kundu G, De S, Abdelmohsen K, Gorospe M. Methods for analysis of circular RNAs. Wiley Interdiscip Rev RNA (2020) 11(1):e1566. doi: 10.1002/wrna.1566</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.1566</ArticleId><ArticleId IdType="pmc">PMC8450895</ArticleId><ArticleId IdType="pubmed">31489773</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe BT, Wesselhoeft RA, Chen R, Anderson DG, Chang HY. Circular RNA migration in agarose gel electrophoresis. Mol Cell (2022) 82(9):1768–1777 e3. doi: 10.1016/j.molcel.2022.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2022.03.008</ArticleId><ArticleId IdType="pmc">PMC9081248</ArticleId><ArticleId IdType="pubmed">35358469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuznetsova I, Rackham O, Filipovska A. Investigating mitochondrial transcriptomes and RNA processing using circular RNA sequencing. Methods Mol Biol (2021) 2192:43–57. doi: 10.1007/978-1-0716-0834-0_4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0834-0_4</ArticleId><ArticleId IdType="pubmed">33230764</ArticleId></ArticleIdList></Reference><Reference><Citation>Verboom K, Everaert C, Bolduc N, Livak KJ, Yigit N, Rombaut D, et al. . SMARTer single cell total RNA sequencing. Nucleic Acids Res (2019) 47(16):e93. doi: 10.1093/nar/gkz535</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz535</ArticleId><ArticleId IdType="pmc">PMC6895261</ArticleId><ArticleId IdType="pubmed">31216024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun (2018) 9(1):2629. doi: 10.1038/s41467-018-05096-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05096-6</ArticleId><ArticleId IdType="pmc">PMC6035260</ArticleId><ArticleId IdType="pubmed">29980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunkhorn S. Improving circular RNA protein yields. Nat Rev Drug Discovery (2022) 21(9):636. doi: 10.1038/d41573-022-00129-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-022-00129-8</ArticleId><ArticleId IdType="pubmed">35879560</ArticleId></ArticleIdList></Reference><Reference><Citation>Orna therapeutics, orna therapeutics raises $221 million series b financing to advance circular RNA platform and accelerate programs to the clinic (Accessed August 16, 2022).</Citation></Reference><Reference><Citation>Yang Q, Li F, He AT, Yang BB. Circular RNAs: Expression, localization, and therapeutic potentials. Mol Ther (2021) 29(5):1683–702. doi: 10.1016/j.ymthe.2021.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.01.018</ArticleId><ArticleId IdType="pmc">PMC8116570</ArticleId><ArticleId IdType="pubmed">33484969</ArticleId></ArticleIdList></Reference><Reference><Citation>Wawrzyniak O, Zarębska Ż, Kuczyński K, Gotz-Więckowska A, Rolle K. Protein-related circular RNAs in human pathologies. Cells (2020) 9(8):1841. doi: 10.3390/cells9081841</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9081841</ArticleId><ArticleId IdType="pmc">PMC7463956</ArticleId><ArticleId IdType="pubmed">32781555</ArticleId></ArticleIdList></Reference><Reference><Citation>Solé C, Lawrie CH. Circular RNAs and cancer: Opportunities and challenges. Adv Clin Chem (2020) 99:87–146. doi: 10.1016/bs.acc.2020.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.acc.2020.02.008</ArticleId><ArticleId IdType="pubmed">32951640</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Yang Y, Li ZQ, Li LC, Zhu XH. Circular RNAs: from biogenesis and function to diseases. Chin Med J (2019) 132(20):2457–64. doi: 10.1097/cm9.0000000000000465</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/cm9.0000000000000465</ArticleId><ArticleId IdType="pmc">PMC6831080</ArticleId><ArticleId IdType="pubmed">31651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M, Dwibedy SLL, Biswal SR, Muthuswamy S, Kumar A, Kumar S, et al. . A novel and potential regulator in pathophysiology of schizophrenia. Metab Brain Dis (2022) 37(5):1309–16. doi: 10.1007/s11011-022-00978-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-022-00978-7</ArticleId><ArticleId IdType="pubmed">35435609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebermann C, Schnarr T, Müller S. Recent advances in understanding circular RNAs. F1000Research (2020) 9:F1000. doi: 10.12688/f1000research.25060.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.25060.1</ArticleId><ArticleId IdType="pmc">PMC7324948</ArticleId><ArticleId IdType="pubmed">32612809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet (2019) 20(11):675–91. doi: 10.1038/s41576-019-0158-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-019-0158-7</ArticleId><ArticleId IdType="pubmed">31395983</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Yang T, Wang W, Xi W, Zhang T, Li Q, et al. . Circular RNAs in immune responses and immune diseases. Theranostics (2019) 9(2):588–607. doi: 10.7150/thno.29678</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.29678</ArticleId><ArticleId IdType="pmc">PMC6376182</ArticleId><ArticleId IdType="pubmed">30809295</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Xiao MS, Li Z, Huang C. New progresses of circular RNA biology: from nuclear export to degradation. RNA Biol (2021) 18(10):1365–73. doi: 10.1080/15476286.2020.1853977</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2020.1853977</ArticleId><ArticleId IdType="pmc">PMC8489929</ArticleId><ArticleId IdType="pubmed">33241761</ArticleId></ArticleIdList></Reference><Reference><Citation>Omata Y, Okawa M, Haraguchi M, Tsuruta A, Matsunaga N, Koyanagi S, et al. . RNA Editing enzyme ADAR1 controls miR-381-3p-mediated expression of multidrug resistance protein MRP4 via regulation of circRNA in human renal cells. J Biol Chem (2022) 298(8):102184. doi: 10.1016/j.jbc.2022.102184</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.102184</ArticleId><ArticleId IdType="pmc">PMC9293778</ArticleId><ArticleId IdType="pubmed">35753353</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol (2020) 21(8):475–90. doi: 10.1038/s41580-020-0243-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-020-0243-y</ArticleId><ArticleId IdType="pubmed">32366901</ArticleId></ArticleIdList></Reference><Reference><Citation>Li I, Chen YG. Emerging roles of circular RNAs in innate immunity. Curr Opin Immunol (2021) 68:107–15. doi: 10.1016/j.coi.2020.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC7925352</ArticleId><ArticleId IdType="pubmed">33176221</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Zhang J, Tian Y, Gao Y, Dong X, Chen W, et al. . CircRNA inhibits DNA damage repair by interacting with host gene. Mol Cancer (2020) 19(1):128. doi: 10.1186/s12943-020-01246-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-020-01246-x</ArticleId><ArticleId IdType="pmc">PMC7446195</ArticleId><ArticleId IdType="pubmed">32838810</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao MS, Ai Y, Wilusz JE. Biogenesis and functions of circular RNAs come into focus. Trends Cell Biol (2020) 30(3):226–40. doi: 10.1016/j.tcb.2019.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2019.12.004</ArticleId><ArticleId IdType="pmc">PMC7069689</ArticleId><ArticleId IdType="pubmed">31973951</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A, Zheng H, Wu Z, Chen M, Huang Y. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics (2020) 10(8):3503–17. doi: 10.7150/thno.42174</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.42174</ArticleId><ArticleId IdType="pmc">PMC7069073</ArticleId><ArticleId IdType="pubmed">32206104</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Timoteo G, Rossi F, Bozzoni I. Circular RNAs in cell differentiation and development. Dev (Cambridge England) (2020) 147(16):dev182725. doi: 10.1242/dev.182725</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.182725</ArticleId><ArticleId IdType="pubmed">32839270</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn VM, Hugouvieux V, Nayak A, Conos SA, Capovilla G, Cildir G, et al. . A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through r-loop formation. Nat Plants (2017) 3:17053. doi: 10.1038/nplants.2017.53</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nplants.2017.53</ArticleId><ArticleId IdType="pubmed">28418376</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Long H, Zheng Q, Bo X, Xiao X, Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer (2019) 18(1):119. doi: 10.1186/s12943-019-1046-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-019-1046-7</ArticleId><ArticleId IdType="pmc">PMC6639939</ArticleId><ArticleId IdType="pubmed">31324186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, et al. . Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun (2016) 7:11215. doi: 10.1038/ncomms11215</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11215</ArticleId><ArticleId IdType="pmc">PMC4823868</ArticleId><ArticleId IdType="pubmed">27050392</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R, Zhang Y, Han B, Bai Y, Zhou R, Gan G, et al. . Circular RNA HIPK2 regulates astrocyte activation via cooperation of autophagy and ER stress by targeting MIR124-2HG. Autophagy (2017) 13(10):1722–41. doi: 10.1080/15548627.2017.1356975</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2017.1356975</ArticleId><ArticleId IdType="pmc">PMC5640207</ArticleId><ArticleId IdType="pubmed">28786753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding C, Yi X, Wu X, Bu X, Wang D, Wu Z, et al. . Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma. Cancer Lett (2020) 479:1–12. doi: 10.1016/j.canlet.2020.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2020.03.002</ArticleId><ArticleId IdType="pubmed">32194140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Wang J, Xiong F, Jiang X, Zhu K, Wang Y, et al. . Epstein-Barr Virus-encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1. Cancer Res (2021) 81(19):5074–88. doi: 10.1158/0008-5472.CAN-20-4321</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-20-4321</ArticleId><ArticleId IdType="pmc">PMC8974435</ArticleId><ArticleId IdType="pubmed">34321242</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Guo X, Wen Y, Huang S, Yuan X, Tang L, et al. . N6-methyladenosine modification opens a new chapter in circular RNA biology. Front Cell Dev Biol (2021) 9:709299. doi: 10.3389/fcell.2021.709299</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.709299</ArticleId><ArticleId IdType="pmc">PMC8342999</ArticleId><ArticleId IdType="pubmed">34368159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Ma R, Zhang X, Cui L, Ding Y, Shi W, et al. . Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions. Mol Cancer (2021) 20(1):121. doi: 10.1186/s12943-021-01415-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-021-01415-6</ArticleId><ArticleId IdType="pmc">PMC8461955</ArticleId><ArticleId IdType="pubmed">34560891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YG, Chen R, Ahmad S, Verma R, Kasturi SP, Amaya L, et al. . N6-methyladenosine modification controls circular RNA immunity. Mol Cell (2019) 76(1):96–109.e9. doi: 10.1016/j.molcel.2019.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2019.07.016</ArticleId><ArticleId IdType="pmc">PMC6778039</ArticleId><ArticleId IdType="pubmed">31474572</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornesello ML, Faraonio R, Buonaguro L, Annunziata C, Starita N, Cerasuolo A, et al. . The role of microRNAs, long non-coding RNAs, and circular RNAs in cervical cancer. Front Oncol (2020) 10:150. doi: 10.3389/fonc.2020.00150</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.00150</ArticleId><ArticleId IdType="pmc">PMC7044410</ArticleId><ArticleId IdType="pubmed">32154165</ArticleId></ArticleIdList></Reference><Reference><Citation>Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. . Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell (2017) 66(1):22–37.e9. doi: 10.1016/j.molcel.2017.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.02.017</ArticleId><ArticleId IdType="pmc">PMC5387670</ArticleId><ArticleId IdType="pubmed">28344082</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG, et al. . And can extend translation duration in vivo. Mol Cell (2019) 74(3):508–520.e4. doi: 10.1016/j.molcel.2019.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2019.02.015</ArticleId><ArticleId IdType="pmc">PMC6724735</ArticleId><ArticleId IdType="pubmed">30902547</ArticleId></ArticleIdList></Reference><Reference><Citation>Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, et al. . Endoribonucleolytic cleavage of m(6)A-containing RNAs by RNase P/MRP complex. Mol Cell (2019) 74(3):494–507.e8. doi: 10.1016/j.molcel.2019.02.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2019.02.034</ArticleId><ArticleId IdType="pubmed">30930054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Wang SK, Belk JA, Amaya L, Li Z. Angel cardenas, et al., engineering circular RNA for enhanced protein production. Nat Biotechnol (2022). doi: 10.1038/s41587-022-01393-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01393-0</ArticleId><ArticleId IdType="pmc">PMC9931579</ArticleId><ArticleId IdType="pubmed">35851375</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrick WC, Pavitt GD. Protein synthesis initiation in eukaryotic cells. Cold Spring Harb Perspect Biol (2018) 10(12):a033092. doi: 10.1101/cshperspect.a033092</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a033092</ArticleId><ArticleId IdType="pmc">PMC6280705</ArticleId><ArticleId IdType="pubmed">29735639</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AG, Grosely R, Petrov AN, Puglisi JD. Dynamics of IRES-mediated translation. Philos Trans R Soc Lond B Biol Sci (2017) 372(1716):20160177. doi: 10.1098/rstb.2016.0177</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2016.0177</ArticleId><ArticleId IdType="pmc">PMC5311923</ArticleId><ArticleId IdType="pubmed">28138065</ArticleId></ArticleIdList></Reference><Reference><Citation>Dave P, George B, Sharma DK, Das S. Polypyrimidine tract-binding protein (PTB) and PTB-associated splicing factor in CVB3 infection: an ITAF for an ITAF. Nucleic Acids Res (2017) 45(15):9068–84. doi: 10.1093/nar/gkx519</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx519</ArticleId><ArticleId IdType="pmc">PMC5587786</ArticleId><ArticleId IdType="pubmed">28633417</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharbi J, Ben M’hadheb-Gharbi M, Souii A. Impaired binding of standard initiation factors eIF3b, eIF4G and eIF4B to domain V of the live-attenuated coxsackievirus B3 Sabin3-like IRES–alternatives for 5'UTR-related cardiovirulence mechanisms. Diagn Pathol (2013) 8:161. doi: 10.1186/1746-1596-8-161</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1746-1596-8-161</ArticleId><ArticleId IdType="pmc">PMC3853319</ArticleId><ArticleId IdType="pubmed">24063684</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecia M, Kokai-Kun JF, Kibbey M, Acharya S, Venema J, Atouf F. COVID-19 vaccine platforms: Delivering on a promise? Hum Vaccin Immunother (2021) 17(9):2873–93. doi: 10.1080/21645515.2021.1911204</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1911204</ArticleId><ArticleId IdType="pmc">PMC8381795</ArticleId><ArticleId IdType="pubmed">34033528</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Expert Committee on Biological Standardization . Annex 3 evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases- regulatory considerations. WHO; (2021).</Citation></Reference><Reference><Citation>World Health Organization . Evaluation of the quality, safety and efficacy of RNA-based. WHO; (2020).</Citation></Reference><Reference><Citation>United States Pharmacopeial Convention . Analytical procedures for mRNA vaccine quality. The United States Pharmacopeial Convention; (2022).</Citation></Reference><Reference><Citation>Center for Drug Evaluation of China . Technical guidelines for pharmaceutical research on mRNA vaccines for the prevention of 2019 novel coronavirus (Trial). Center for Drug Evaluation of China; (2020).</Citation></Reference><Reference><Citation>EUROPEAN MEDICINES AGENCY . EMA-consideration on core requirements for RMPs of COVID-19 vaccines. European Medicines Agency; (2022).</Citation></Reference><Reference><Citation>Food and Drug Administration . Q&amp;A for spikevax (COVID-19 vaccine mRNA). European Medicines Agency; (2022).</Citation></Reference><Reference><Citation>Food and Drug Administration . Q&amp;A for comirnaty (COVID-19 vaccine mRNA). Food and Drug Administration; (2022).</Citation></Reference><Reference><Citation>EUROPEAN MEDICINES AGENCY EMA-reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2. European Medicines Agency; (2021).</Citation></Reference><Reference><Citation>Oberstra J, Schonborn J, Breyel1 E, Tittgen J, Schumacher J, Lukacs N. Monoclonal antibodies to double-stranded RNA as probes. Nucleic Acids Res (1991) 19(11):2993. doi: 10.1093/nar/19.11.2993</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/19.11.2993</ArticleId><ArticleId IdType="pmc">PMC328262</ArticleId><ArticleId IdType="pubmed">2057357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonin M, Oberstraß JÜRgen, Lukacs N, Ewert K, Oesterschulze E, Kassing R, et al. . Determination of preferential binding sites for anti-dsRNA antibodies on double-stranded RNA by scanning force microscopy. Rna (2000) 6(4):563–70. doi: 10.1017/s1355838200992318</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s1355838200992318</ArticleId><ArticleId IdType="pmc">PMC1369937</ArticleId><ArticleId IdType="pubmed">10786847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen EW, Nelson J, Mintri S, Rabideau AE, Zheng W, Besin G, et al. . Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci Adv (2020) 6:eaaz6893. doi: 10.1126/sciadv.aaz6893</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz6893</ArticleId><ArticleId IdType="pmc">PMC7314518</ArticleId><ArticleId IdType="pubmed">32637598</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoltán Kis Simon D, Kontoravdi C, Shah N. A blueprint for quality by digital design to support rapid RNA vaccine process development, manufacturing &amp; supply. accine Insights (2022) 1(4):219–33. doi: 10.18609/vac.2022.33</Citation><ArticleIdList><ArticleId IdType="doi">10.18609/vac.2022.33</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel S, Kis Z, Kontoravdi C, Shah N. Quality by design for enabling RNA platform production processes. Trends Biotechnol (2022) 40(10):1213–28. doi: 10.1016/j.tibtech.2022.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2022.03.012</ArticleId><ArticleId IdType="pubmed">35491266</ArticleId></ArticleIdList></Reference><Reference><Citation>Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI, Cooke JP. The limitless future of RNA therapeutics. Front Bioeng Biotechnol (2021) 9:628137. doi: 10.3389/fbioe.2021.628137</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2021.628137</ArticleId><ArticleId IdType="pmc">PMC8012680</ArticleId><ArticleId IdType="pubmed">33816449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadman M. The overlooked superpower of mRNA vaccines. Science (2021) 373(6554):479. doi: 10.1126/science.373.6554.479</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.373.6554.479</ArticleId><ArticleId IdType="pubmed">34326217</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart LM. In gratitude for mRNA vaccines. N Engl J Med (2021) 385(15):1436–8. doi: 10.1056/NEJMcibr2111445</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr2111445</ArticleId><ArticleId IdType="pubmed">34569728</ArticleId></ArticleIdList></Reference><Reference><Citation>Topol EJ. Messenger RNA vaccines against SARS-CoV-2. Cell (2021) 184(6):1401. doi: 10.1016/j.cell.2020.12.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.039</ArticleId><ArticleId IdType="pmc">PMC7805392</ArticleId><ArticleId IdType="pubmed">33740443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Blum J, Thanh Le T, Havelange N, Magini D, Yoon IK. The mRNA vaccine development landscape for infectious diseases. Nat Rev Drug Discovery (2022) 21(5):333–4. doi: 10.1038/d41573-022-00035-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-022-00035-z</ArticleId><ArticleId IdType="pubmed">35149859</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CX, Guo SK, Nan F, Xu YF, Yang L, Chen LL. RNA Circles with minimized immunogenicity as potent PKR inhibitors. Mol Cell (2022) 82(2):420–434.e6. doi: 10.1016/j.molcel.2021.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2021.11.019</ArticleId><ArticleId IdType="pubmed">34951963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity (2005) 23(2):165–75. doi: 10.1016/j.immuni.2005.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId><ArticleId IdType="pubmed">16111635</ArticleId></ArticleIdList></Reference><Reference><Citation>Paramasivam A, Vijayashree Priyadharsini J. Novel insights into m6A modification in circular RNA and implications for immunity. Cell Mol Immunol (2020) 17(6):668–9. doi: 10.1038/s41423-020-0387-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0387-x</ArticleId><ArticleId IdType="pmc">PMC7264242</ArticleId><ArticleId IdType="pubmed">32152551</ArticleId></ArticleIdList></Reference><Reference><Citation>Flemming A. The enigma of circular RNA. Nat Rev Immunol (2019) 19(6):351. doi: 10.1038/s41577-019-0173-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0173-0</ArticleId><ArticleId IdType="pubmed">31053750</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Wu J, Yao S, Xu Y, Zhao W, Tong Y, et al. . DeepCIP: a multimodal deep learning method for the prediction of internal ribosome entry sites of circRNAs. bioRxiv preprint server Biol (2022). doi: 10.1101/2022.10.03.510726</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.03.510726</ArticleId><ArticleId IdType="pubmed">37542919</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Gyawali D, Yerabolu R, Schariter J, White P. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nat Commun (2021) 12(1):6777. doi: 10.1038/s41467-021-26926-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26926-0</ArticleId><ArticleId IdType="pmc">PMC8608879</ArticleId><ArticleId IdType="pubmed">34811367</ArticleId></ArticleIdList></Reference><Reference><Citation>Azarpanah H, Farhadloo M, Vahidov R, Pilote L. Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases. BMC Public Health (2021) 21(1):1686. doi: 10.1186/s12889-021-11745-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11745-1</ArticleId><ArticleId IdType="pmc">PMC8444164</ArticleId><ArticleId IdType="pubmed">34530804</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, Li S, Feng Y, He Y, Hong W, Ye Z. A novel circular RNA (hsa_circ_0059930)-mediated miRNA-mRNA axis in the lipopolysaccharide-induced acute lung injury model of MRC-5 cells. Bioengineered (2021) 12(1):1739–51. doi: 10.1080/21655979.2021.1916276</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1916276</ArticleId><ArticleId IdType="pmc">PMC8806270</ArticleId><ArticleId IdType="pubmed">34002668</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B, Kaur P, Cedeno L, Brahimi T, Patel P, Virk H, et al. . COVID-19 mRNA vaccine and myocarditis. Eur J Case Rep Internal Med (2021) 8(7):2681. doi: 10.12890/2021_002681</Citation><ArticleIdList><ArticleId IdType="doi">10.12890/2021_002681</ArticleId><ArticleId IdType="pmc">PMC8276934</ArticleId><ArticleId IdType="pubmed">34268277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>